Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis

Journal of Clinical Pharmacology

Volumn 54, Issue 2, 2014, Pages 189-200

  Peng, Hong ^a   Liu, Junying ^a   Yang, Min ^a   Tong, Shiwen ^a   Yin, Wenwei ^a   Tang, Hui ^a   Hu, Peng ^a   Hu, Huaidong ^a   Ren, Hong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B associated decompensated cirrhosis; Enticavir; Lamivudine plus adefovir dipivoxil; Meta analysis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHILD TURCOTTE PUGH SCORE; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DRUG COMBINATION; FEMALE; HEPATITIS B, CHRONIC; LIVER CIRRHOSIS; MALE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VIROLOGY;

ADENINE; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CREATININE; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84895767665     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.181     Document Type: Article

References (47)

1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45:507-539.
3. Alter MJ. Epidemiology and prevention of hepatitis B; 2003. Copyright# 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.:+ 1 (212) 584-4662. 039-046.
4. Organization WH. Hepatitis B: World Health Organization fact sheet 204. 2000.
5. Organization WH. The world health report 2003: Shaping the future. Geneva: WHO, 2010; 2003. Annex table 2: 156.
6. Vallet-Pichard A, Mallet V, Costentin CE, Pol S. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther. 2009;7:527-535.
7. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: A long-term follow-up study. Hepatol Int. 2007;1:267-273.
8. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886-2895.
9. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
10. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int. 2008;2:263-283.
11. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology. 2001;34:411-416.
12. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000;33:308-312.
13. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for waitlisted and post-liver transplantation patients with lamivudineresistant hepatitis B: Final long-term results. Liver Transpl. 2007; 13:349-360.
14. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995;109:908-916.
15. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology. 2011;54:91-100.
16. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999;30:567-572.
17. de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol. 1998;29:669-675.
18. Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology. 2009;49:S122-S128.
19. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15: 1356-1361.
20. Jayakumar R, Joshi YK, Singh S. Laboratory evaluation of three regimens of treatment of chronic hepatitis B: Tenofovir, entecavir and combination of lamivudine and adefovir. J Lab Physicians. 2012;4:10-16.
21. Jia H, Ma K, Lv G, Zheng L, Yang Y. Efficacy comparison of lamivudine combined with adefovir dipivoxil de novo and entecavir monotherapy in treatment of patients with hepatitis B virus-related decompensated cirrhosis. Chin Pharm J. 2012;47:1453-1456.
22. Lin ZZ, Tan B, Zhou HJ. Comparison of 48-week Efficacy between lamivudine combined with adefovir and entecavir in patients with hepatitis B virus related cirrhosis. J Clin Ration Drug Use. 2011;27:010.
23. Yang J, Fan H. Comparison of efficacy of nucleot(s)ide analogues in patients with hepatitis B virus-induced decompensated cirrhosis. Med Innov China. 2012;9:1-2.
24. Li B, Li F, Ji D, et al. Clinical observation on 69 cases of decompensated cirrhosis patients following chronic hepatitis B virus infection treated with entecavir and other nucleosidc drugs. Chin Hepatol. 2010;15:8-10.
25. Ma J, Xu Z. Efficacy between Lamivudine combined with adefovir and entecavir monotherapy in 42 patients with hepatitis B virus related cirrhosis. Anti Infect Pharm. 2010;7:292-294.
26. Qiu Y, Huang L, Zhou H, et al. The efficacy of antiviral therapy for hepatitis B virus related decompensated cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 2011;19:130-131.
27. Li S, Zhang X. The efficacy of antiviral therapy for hepatitis B virus related decompensated cirrhosis. Yiayao Qianyan. 2012; 103-104.
28. Wang J-H, Lu S-N, Lee C-M, Lee J-F, Chou Y-P. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol. 2002;37:366-369.
29. Chang T-T, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010.
30. Lai C-L, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-1020.
31. Liaw YF, Sheen I, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53: 62-72.
32. Han Y, Huang LH, Liu CM, et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. J Gastroenterol Hepatol. 2009;24:1417-1423.
33. Fung S, Mazzulli T, Sherman M, et al. 688 Pre-existing antiviral resistance mutations among treatment-naive hbv patients can be detected by a sensitive line probe assay. J Hepatol. 2008;48:S256-S256.
34. Lv G-C, Yao J-M, Yang Y-D, et al. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol. 2013;19:3481-3486.
35. Ghany M-G, Feld J-J, Zhao X, et al. Randomised clinical trial: The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. Aliment Pharmacol Ther. 2012; doi: 10.1111/ j.1365-2036.2012.05059. x
36. Wang L-C, Chen E-Q, Cao J, et al. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol Int. 2011;5:671-676.
37. Carey I, Mendes A, Joshi D, et al. 707 Long-term de-novo lamivudine adefovir combination therapy in chronic hepatitis B is efficient, but has negative impact on renal/bone safety in comparison to entecavir monotherapy. J Hepatol. 2011;54:2.
38. Yu J, Shi J, Wu J, et al. Efficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2011;19:88.
39. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatmentnaive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52:176-182.
40. GM K. Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs. 2011;71:857-861.
41. Sung J, Lai J-Y, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAgpositive chronic hepatitis B. J Hepatol. 2008;48:728.
42. Wensing AM, van Maarseveen NM, Nijhuis M, Fifteen years of HIV protease inhibitors: Raising the barrier to resistance. Antiviral Res. 2010;85:59-74.
43. Colgrove R, Japour A, A combinatorial ledge: Reverse transcriptase fidelity, total body viral burden, and the implications of multipledrug HIV therapy for the evolution of antiviral resistance. Antiviral Res. 1999;41:45-56.
44. Locarnini S. Primary resistance, multidrug resistance, and crossresistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2:147-151.
45. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009;50:2001-2006.
46. Singal A, Fontana R. Meta-analysis: Oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther. 2012;35:674-689.
47. Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAgpositive chronic hepatitis B. Pharmacoeconomics. 2007;25:963-977.